Tauns Laboratories, Inc. (197A) Price & Analysis

Compare

0 Followers

197A Stock Chart & Stats

¥509.00

¥4.00(0.67%)

At close: Jan 08 4:00 PM EST

¥509.00

¥4.00(0.67%)

Day’s Range― - ―

52-Week Range¥418.00 - ¥618.00

Previous CloseN/A

Volume864.10K

Average Volume (3M)400.80K

Market Cap

¥56.29B

Enterprise Value¥74.50B

Total Cash (Recent Filing)¥9.27B

Total Debt (Recent Filing)¥14.42B

Price to Earnings (P/E)14.8

Beta0.48

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield5.09%

Share Statistics

EPS (TTM)N/A

Shares Outstanding106,404,150

10 Day Avg. Volume355,040

30 Day Avg. Volume400,796

Financial Highlights & Ratios

PEG Ratio1.16

Price to Book (P/B)3.14

Price to Sales (P/S)2.94

P/FCF Ratio25.61

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Profitability & MarginsConsistent revenue growth and high gross/net margins indicate durable operating strength. These margins support sustained R&D and commercialization spending, improve resilience to demand cycles, and provide structural capacity to generate shareholder returns and fund strategic initiatives over months.

Improving Cash GenerationA marked improvement in free cash flow and solid operating cash flow relative to net income enhances internal funding for capex, R&D, and partnerships. Strong cash conversion reduces reliance on external capital and supports durable financial flexibility over the medium term.

Balance Sheet Strength & Capital EfficiencyA robust equity base with manageable leverage and high ROE signals efficient capital allocation and financial stability. This structural strength underpins long-term investing capacity, partner confidence, and the ability to pursue M&A or licensing without excessive dilution.

Bears Say

Rising Debt LevelsAn upward trend in total debt raises leverage and interest obligations, which can constrain strategic flexibility and heighten refinancing risk. If cash flow weakens, rising debt may pressure liquidity and limit the company’s ability to invest in long‑term projects or respond to industry shifts.

Free Cash Flow VolatilityVolatile free cash flow and a prior negative operating cash flow create uncertainty around sustainable internal funding. This variability can force reliance on external financing, increase funding costs, and weaken the firm’s capacity to consistently fund R&D, dividends, or strategic partnerships.

Gross Profit Decline / Cost PressureA declining gross profit signals emerging cost or pricing pressure that can erode durable margins. If unchecked, this could compress EBITDA and net margins, forcing pricing moves or cost cuts that may impair competitive position or slow product investment over several quarters.

Tauns Laboratories, Inc. News

Tauns Laboratories Issues FY2026 Q2 Financial Highlights

The latest update is out from Tauns Laboratories, Inc. ( ($JP:197A) ). Tauns Laboratories, Inc. has released a...

10d ago

197A

Tauns Laboratories Profit Halves on Lower Sales but Keeps Full-Year Outlook and Dividend Plan

Tauns Laboratories, Inc. ( ($JP:197A) ) just unveiled an announcement. Tauns Laboratories reported a sharp year-on-year decline for...

10d ago

197A

TAUNS Laboratories Acquires CLAIRVO TECHNOLOGIES to Boost Diagnostic Innovations

The latest update is out from Tauns Laboratories, Inc. ( ($JP:197A) ). TAUNS Laboratories, Inc. has announced its...

3M ago

197A

Tauns Laboratories Faces Financial Decline but Projects Recovery

Tauns Laboratories, Inc. ( ($JP:197A) ) has provided an announcement. Tauns Laboratories, Inc. reported a significant decline in...

3M ago

197A

Tauns Laboratories Revises Dividend Forecast for FY 2026

An update from Tauns Laboratories, Inc. ( ($JP:197A) ) is now available. Tauns Laboratories, Inc. has announced a...

3M ago

197A

Tauns Laboratories Reports Modest Growth and Positive Outlook

Tauns Laboratories, Inc. ( ($JP:197A) ) has issued an update. Tauns Laboratories, Inc. reported its financial results for...

6M ago

197A

TAUNS Laboratories Withdraws Prime Market Application

An update from Tauns Laboratories, Inc. ( ($JP:197A) ) is now available. TAUNS Laboratories, Inc. has decided to...

7M ago

197A

TAUNS Laboratories’ Shares Selected for Loan Margin Trading

The latest announcement is out from Tauns Laboratories, Inc. ( ($JP:197A) ). TAUNS Laboratories, Inc. announced that its...

8M ago

197A

Tauns Laboratories Reports Growth in Nine-Month Financial Results

The latest announcement is out from Tauns Laboratories, Inc. ( ($JP:197A) ). Tauns Laboratories, Inc. reported a 7.6%...

10M ago

197A

TAUNS Laboratories Seeks Prime Market Listing on Tokyo Stock Exchange

Tauns Laboratories, Inc. ( ($JP:197A) ) has shared an announcement. TAUNS Laboratories, Inc. has applied to change its...

10M ago

197A

197A FAQ

What was Tauns Laboratories, Inc.’s price range in the past 12 months?

Tauns Laboratories, Inc. lowest stock price was ¥418.00 and its highest was ¥618.00 in the past 12 months.

What is Tauns Laboratories, Inc.’s market cap?

Tauns Laboratories, Inc.’s market cap is ¥56.29B.

When is Tauns Laboratories, Inc.’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Tauns Laboratories, Inc.’s earnings last quarter?

Currently, no data Available

Is Tauns Laboratories, Inc. overvalued?

According to Wall Street analysts Tauns Laboratories, Inc.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Tauns Laboratories, Inc. pay dividends?

Tauns Laboratories, Inc. pays a Annually dividend of ¥14 which represents an annual dividend yield of 5.09%. See more information on Tauns Laboratories, Inc. dividends here

What is Tauns Laboratories, Inc.’s EPS estimate?

Tauns Laboratories, Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Tauns Laboratories, Inc. have?

Tauns Laboratories, Inc. has 106,404,150 shares outstanding.

What happened to Tauns Laboratories, Inc.’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Tauns Laboratories, Inc.?

Currently, no hedge funds are holding shares in JP:197A

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Tauns Laboratories, Inc.

TAUNS Laboratories, Inc. develops and manufactures vitro diagnostic drugs & measuring instruments. It also provides import and export of industrial measuring instruments, medical, physical, chemical and measuring instruments. The company was founded in April 1987 and is headquartered in Izunokuni, Japan.